Skip to main content
. 2010 Jan 1;137(1):113–122. doi: 10.1242/dev.043174

Fig. 7.

Fig. 7.

Delayed expression of STM and the provascular enhancer trap E2331 in gct and cct. (A-D) Expression of a pSTM::GUS transcriptional fusion (Kirch et al., 2003) in wild-type globular (A), transition (B), heart (C) and torpedo (D) stage embryos. (E) Detection of STM mRNA by in situ hybridization in wild-type bent cotyledon stage embryos. (F-M) pSTM::GUS expression is not seen in gct or cct embryos at the transition (F,J) or heart (G,K) stages. Torpedo stage gct and cct embryos initiate pSTM::GUS expression (H,L), and bent cotyledon stage gct and cct embryos show an expanded STM expression domain (I,M). (N-Q) Enhancer trap marker E2331 is expressed in vascular primorida of globular (N), heart (O), torpedo (P) and bent cotyledon (Q) stage embryos. (R-Y) gct and cct embryos at the globular (R,V) and heart (S,W) stages do not express E2331. Beginning at the torpedo stage, E2331 expression begins in lower vascular primordia of gct (T) and cct (X) embryos. At the bent cotyledon stage, E2331 is expressed throughout vascular primordia of gct (U) and cct (Y) embryos. Scale bars: 20 μm.

HHS Vulnerability Disclosure